Alloimmunization in myelodysplastic syndrome is associated with higher healthcare costs, longer hospitalizations, and increased mortality

• DOI: 10.1111/trf.17966
• Publication Date: 2024-08-07T10:40:06Z
• Authors: Elisabet Viayna; Eric A. Gehrie; Christopher Blanc...
• Keywords: 03 medical and health sciences; 0302 clinical medicine

Transfusion of red blood cells (RBC) is an important component treatment for myelodysplastic syndromes (MDS). Patients receiving frequent transfusions are more likely to develop alloimmunization, immune reaction minor RBC antigens that increases the risk complications including delayed hemolysis. Phenotypic matching believed reduce alloimmunization although rigorous evidence lacking. This study examines association with clinical and economic outcomes may give insight into potential benefit phenotypic in MDS.